Pronunciation: tin-ZAP-a-rin SOE-dee-um
Class: Low molecular weight heparin
- Injection, solution 20,000 units/mL
Inhibits reactions that lead to the clotting of blood, including the formation of fibrin clots.
T max is approximately 4 to 5 h and C max is approximately 0.25 to 0.87 units/mL. Bioavailability is 86.7%.
Vd is 3.1 to 5 L.
Partially metabolized by desulphation and depolymerization.
Half-life is approximately 3 to 4 h. Cl is approximately 1.7 L/h and the primary route of elimination is renal.
Special PopulationsRenal Function Impairment
A reduction in Cl in moderate (30 to 50 mL/min) and severe (less than 30 mL/min) renal impairment was observed. Patients with severe renal impairment exhibited a 24% reduction in tinzaparin Cl. Administer to patients with severe renal impairment with caution.Hepatic Function Impairment
No prospective studies have assessed tinzaparin pharmacokinetics patients with hepatic impairment. However, the hepatic route is not a major route of elimination.Elderly
Because renal function is known to decline with age, elderly patients may show reduced elimination of tinzaparin.Weight
Weight is an important factor for the prediction of tinzaparin Cl.
Indications and Usage
Treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered with warfarin.
Venous thromboembolism prophylaxis in general or gynecologic surgery; prophylaxis of DVT, which may lead to pulmonary embolism, in patients undergoing orthopedic surgery, hip fracture surgery, or neurosurgery who are at risk for thromboembolic complications.
Active major bleeding; patients with or history of heparin-induced thrombocytopenia; hypersensitivity to tinzaparin, heparin, sulfites, benzyl alcohol, or pork products.
Dosage and AdministrationAdults
Subcutaneous 175 anti-Xa units/kg once daily for more than 6 days and until patient is adequately anticoagulated with warfarin (INR of at least 2 for two consecutive days). Initiate warfarin therapy when appropriate (usually within 1 to 3 days of tinzaparin initiation).
- Administer by subcutaneous injection. Do not administer by IM or IV injection.
- Place the patient in the supine or sitting position before administration.
- Alternate injection sites between the left and right anterolateral and left and right posterolateral abdominal wall.
- Hold skinfold between the thumb and forefinger until the injection is completed.
- Introduce the full length of the needle into the skinfold and inject without aspiration.
- To minimize bruising, do not rub the injection site after completion of the injection.
- Do not mix with other injections or infusions.
- Inspect visually for particulate matter and discoloration prior to administration.
Store at 59° to 86°F.
The risk of severe bleeding may be increased. Close clinical and laboratory monitoring (aPTT and/or anti-Xa) is indicated during coadministration of tinzaparin and antithrombin. Adjust the dose of tinzaparin accordingly. Reduced doses of tinzaparin are recommended when coadministered with antithrombin III.Drugs that increase the risk of bleeding (eg, oral anticoagulants [eg, warfarin], platelet inhibitors [eg, clopidogrel], dextran, dipyridamole, NSAIDs, salicylates, sulfinpyrazone, ticlopidine], thrombolytics [eg, tenecteplase])
Use with caution because of increased risk of bleeding.SSRIs (eg, fluoxetine)
The risk of severe bleeding may be increased. Carefully monitor the coagulation status of the patient and observe the patient for bleeding. Adjust therapy as needed.
Laboratory Test Interactions
Asymptomatic reversible increases in AST and ALT concentrations.
Angina pectoris, deep leg thrombophlebitis, deep thrombophlebitis, hypertension, hypotension, tachycardia (1% or more); peripheral ischemia (postmarketing).
Headache (2%); confusion, dizziness, insomnia (1% or more).
Bullous eruption, erythematous rash, pruritus, skin disorder (1% or more); rash (1%); cutis aplasia of the scalp, epidermal necrolysis, ischemic necrosis, Steven-Johnson syndrome, urticaria (postmarketing).
Nausea (2%); flatulence, GI disorder (1% or more); abdominal pain, constipation, diarrhea, vomiting (1%); rectal bleeding (postmarketing).
UTI (4%); dysuria, urinary retention (1% or more); hematuria (1%); priapism (postmarketing).
Epistaxis, hemorrhage (2%); anemia, bleeding, hematoma, thrombocytopenia (1% or more); agranulocytosis, pancytopenia, thrombocythemia (postmarketing).
Elevated ALT (13%); elevated AST (9%); cholestatic hepatitis, increase in hepatic enzymes (postmarketing).
Hematoma (16%); mild local irritation, pain, and ecchymosis.
Pulmonary embolism (2%); dyspnea (1%); pneumonia; respiratory disorder (1% or more).
Back pain, chest pain, fever, pain (2%); healing impaired, infection, reaction unclassified (1% or more); anaphylactoid reactions; abscess, acute febrile reaction, allergic purpura, angioedema, hemoptysis, necrosis, neonatal hypotonia, ocular hemorrhage (postmarketing).
Risk of spinal/epidural hematomas is increased in patients receiving neuraxial anesthesia or spinal puncture and who are anticoagulated with low molecular weight heparins or heparinoids. These hematomas may result in long-term or permanent paralysis. Other risk factors include indwelling epidural catheters, repeated/traumatic epidural/spinal puncture, concomitant use of other drugs affecting hemostasis (eg, NSAIDs, platelet inhibitors, anticoagulants), a history of traumatic or repeated epidural or spinal punctures, and a history of spinal deformity or spinal surgery. Monitor patients frequently for signs and symptoms of neurological impairment. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.
Periodic CBC, including platelet count and hemacrit or hemoglobin, and stool tests for occult blood are recommended during treatment. Monitor patients frequently for signs and symptoms of neurological impairment. Carefully monitor pregnant women for evidence of bleeding or excessive anticoagulation.
Category B .
Safety and efficacy not established.
May increase the risk of death, compared with unfractionated heparin, when administered to elderly patients with renal insufficiency.
Allergic-type reactions may occur.
Effect of tinzaparin may be prolonged. Use with caution. May increase the risk of death compared with unfractionated heparin when administered to elderly patients with renal insufficiency.
Special Risk Patients
Use drug with caution in patients with diabetic retinopathy, bleeding diathesis, uncontrolled arterial hypertension, or history of recent GI ulceration and hemorrhage.
Fatal gasping syndrome
Fatal gasping syndrome in premature infants has been associated with the benzyl alcohol preservative present in tinzaparin.
Use with caution in conditions with increased risk of hemorrhage (eg, bacterial endocarditis, severe uncontrolled hypertension, active ulcerative GI disease).
Cannot be used interchangeably (unit for unit) with heparin or other low molecular weight heparins.
Has been reported as a rare occurrence.
Tinzaparin contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes, in certain susceptible people.
Bleeding complications, blood in urine, bruising, frank bleeding, nosebleeds, petechial hemorrhage, tarry stools.
- Instruct patient to take safety precautions to avoid cuts and bruises (eg, soft toothbrush, electric razor, handrails).
- Caution patient to avoid aspirin or other OTC anticoagulants.
- Instruct patients to report any current or future prescription, OTC, or herbal medication use to primary care provider.
- Advise patient to report bruises; bleeding; nosebleeds; bleeding gums; coffee-ground emesis; red-flecked sputum; or tarry, black, or red stools.
Copyright © 2009 Wolters Kluwer Health.